How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →

NiKang Therapeutics® Announces First Patient Dosed in a Phase 1b/2 Study of NKT2152 in Combination with Standard-of-Care in First-Line Regimen for Hepatocellular Carcinoma

calendar_today January 21, 2025 person Elizabeth Aspinall domain nikang-therapeutics

See the press release on Business Wire